Deep sequencing for HIV-1 clinical management

Maria Casadellà, Roger Paredes

    Research output: Contribution to journalReview articleResearchpeer-review

    27 Citations (Scopus)

    Abstract

    © 2016 Elsevier B.V. The emerging HIV-1 resistance epidemic is threatening the impressive global advances in HIV-1 infection treatment and prevention achieved in the last decade. Next-generation sequencing is improving our ability to understand, diagnose and prevent HIV-1 resistance, being increasingly cost-effective and more accessible. However, NGS still faces a number of limitations that need to be addressed to enable its widespread use. Here, we will review the main NGS platforms available for HIV-1 diagnosis, the factors affecting the clinical utility of NGS testing and the evidence supporting −or not- ultrasensitive genotyping over Sanger sequencing for routine HIV-1 diagnosis. Now that global HIV-1 eradication might be within our reach, making NGS accessible also to LMICs has become a priority. Reductions in sequencing costs, particularly in library preparation, and accessibility to low-cost, robust but simplified automated bioinformatic analyses of NGS data will remain essential to end the HIV-1 pandemic.
    Original languageEnglish
    Pages (from-to)69-81
    JournalVirus Research
    Volume239
    DOIs
    Publication statusPublished - 15 Jul 2017

    Keywords

    • Antiretroviral therapy
    • HIV resistance
    • HIV-1
    • Low-frequency variants
    • Next-generation sequencing
    • Tropism

    Fingerprint Dive into the research topics of 'Deep sequencing for HIV-1 clinical management'. Together they form a unique fingerprint.

    Cite this